ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Sevilla, AN, ESP:

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...

Active, not recruiting
Ovarian Cancer
Drug: placebo + avastin + platinum-based chemotherapy
Drug: atezolizumab + avastin + platinum-based chemotherapy

Phase 3

ARCAGY/ GINECO GROUP

Sevilla, Spain and 74 other locations

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...

Enrolling
Chemotherapy-induced Thrombocytopenia
Drug: Placebo
Drug: Romiplostim

Phase 3

Amgen
Amgen

Sevilla, Andalucía, Spain and 128 other locations

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1s...

Active, not recruiting
Recurrent Ovarian Carcinoma
Drug: Chemotherapy
Drug: Bevacizumab

Phase 3

AGO Research

Jerez De La Frontera, Spain and 110 other locations

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...

Active, not recruiting
Ovarian Neoplasms
Drug: Placebo
Drug: Niraparib

Phase 3

Tesaro
Tesaro

Sevilla, Spain and 196 other locations

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal....

Enrolling
Endometrial Cancer
Esophageal Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks

Phase 1

Adaptimmune

Sevilla, Spain and 21 other locations

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Placebo Oral Tablet
Drug: Rucaparib

Phase 3

pharmaand

Sevilla, Spain and 237 other locations

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Peritoneal Neoplasms
Fallopian Tube Cancer
Drug: Docetaxel
Drug: Placebo for olaparib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Sevilla, Spain and 226 other locations

Locations recently updated

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....

Enrolling
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: T- Dxd

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Sevilla, Spain and 76 other locations

A Study of SGN-B6A in Advanced Solid Tumors

to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A s...

Enrolling
Uterine Cervical Neoplasms
Ovarian Neoplasms
Drug: carboplatin
Drug: pembrolizumab

Phase 1

Seagen
Seagen

Jerez de la Frontera, Other, Spain and 44 other locations

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors th...

Active, not recruiting
Breast Cancer
Neuroendocrine Tumors
Drug: Entrectinib

Phase 2

Roche
Roche

Sevilla, Spain and 122 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems